Results 191 to 200 of about 27,357 (285)

Current Advances of Treatments, Therapeutic Targets, Biomarkers, Novel Drugs, and Machine Learning for Hypopharyngeal Squamous Cell Carcinoma

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Hypopharyngeal squamous cell carcinoma (HSCC) is an aggressive subtype of head and neck squamous cell carcinoma with insidious onset, early metastasis, and dismal prognosis. Conventional multimodal therapy achieves limited survival benefit, highlighting an urgent need for refined precision strategies.
Ce Li   +12 more
wiley   +1 more source

TOM1 family proteins: from cargo sorting to immune dysregulation and cancer. [PDF]

open access: yesCell Commun Signal
Collins MV   +5 more
europepmc   +1 more source

From lipid dynamics to precision predictions: A new approach methodology for precision modeling of phosphoinositide signaling

open access: hybrid
Gonzalo Hernandez-Hernandez   +6 more
openalex   +1 more source

Integrated Multi‐Omics Analysis Reveals the Genetic Basis of Phenotypic Variation in Tibetan Sheep

open access: yesIntegrative Zoology, EarlyView.
SNaPshot‐validated GWAS results demonstrated significant correlations between candidate single nucleotide polymorphisms (SNPs) and body size traits in Tibetan sheep. Concurrently, hematoxylin and eosin staining, alongside muscle fiber analysis, confirmed pronounced morphological differences in muscle tissue between sheep of varying conformation.
Dehui Liu   +16 more
wiley   +1 more source

Long-tailed class I myosins rely on tail-mediated phosphoinositide recognition for specific membrane recruitment. [PDF]

open access: yesCell Commun Signal
Rajendraprasad G   +8 more
europepmc   +1 more source

Umbilical Cord Blood–Derived Extracellular Vesicles Enhance Neurovascular Regeneration and Improve Erectile Function in a Mouse Model of Bilateral Cavernous Nerve Injury

open access: yesAndrology, EarlyView.
ABSTRACT Background Erectile dysfunction (ED) secondary to cavernous nerve injury (CNI), such as that occurring after radical prostatectomy, remains a significant clinical challenge, particularly among patients who do not respond to phosphodiesterase Type 5 inhibitors (PDE5i).
Minh Nhat Vo   +6 more
wiley   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

open access: yesBritish Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy